New vaccines for the prevention of tuberculosis in human immunodeficiency virus infection

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 6, 2012, Pages 718-723

  Von Reyn, C F ^a   Bakari, M ^b   Arbeit, R D ^c   Lahey, T ^a   Ramadhani, A ^d   Egwag, S ^e  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d National AIDS Control Program   (Tanzania)

^e National Programme on Tuberculosis and Leprosy   (Tanzania)

Author keywords

HIV infection; Mycobacterium vaccae; Tanzania; Tuberculosis vaccines

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIAL VACCINE; BCG VACCINE; INACTIVATED WHOLE CELL MYCOBACTERIUM VACCAE VACCINE; ISONIAZID; MODIFIED VACCINIA ANKARA ANTIGEN 85 A VACCINE; MYCOBACTERIUM VACCINE; PLACEBO; UNCLASSIFIED DRUG; VPM 1002;

BCG VACCINATION; CASE FINDING; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; MIXED INFECTION; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TANZANIA; TUBERCULIN TEST; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; DELIVERY OF HEALTH CARE, INTEGRATED; HIV INFECTIONS; HUMANS; ISONIAZID; PREVENTIVE HEALTH SERVICES; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84861179999     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0444     Document Type: Review

References (49)

1. Harries A D, Zachariah R, Corbett E L, et al. The HIV-associated tuberculosis epidemic-when will we act? Lancet 2010; 375: 19619.
2. Houben R M G J, Crampin A C, Ndhlovu R, et al. Human immuno deficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. Int J Tuberc Lung Dis 2011; 15: 24-31.
3. von Reyn C F, Kimambo S, Mtei L, et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 2011; 15: 1087-1092.
4. Glynn J R, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis. J Infect Dis 2010; 201: 704-711.
5. von Reyn C F, Mtei L, Arbeit R D, et al. Prevention of tuberculosis in bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24: 675-685.
6. Corbett E L, Bandason T, Duong T, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a clusterrandomised trial. Lancet 2010; 376: 1244-1253.
7. Sekandi J N, Neuhauser D, Smyth K, Whalen C C. Active case finding of undetected tuberculosis among chronic coughers in a slum setting in Kampala, Uganda. Int J Tuberc Lung Dis 2009; 13: 508-513.
8. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010; 14: 1233-1243.
9. Sonnenberg P, Glynn J R, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191: 150-158. (Pubitemid 40096371)
10. Lawn S D, Myer L, Bekker L G, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-1612. (Pubitemid 44162402)
11. Tabarsi P, Saber-Tehrani A S, Baghaei P, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 2009; 12: 14.
12. Golub J E, Durovni B, King B S, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22: 2527-2533.
13. Lawn S D, Wood R, De Cock K M, Kranzer K, Lewis J J, Churchyard G J. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10: 489-498.
14. Lawn S D, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resourcelimited settings. Clin Chest Med 2009; 30: 685-699, viii.
15. Grant A D, Charalambous S, Fielding K L, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005; 293: 2719-2725. (Pubitemid 40965083)
16. Golub J E, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23: 631-636.
17. Bucher H C, Griffith L E, Guyatt G H, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13: 501-507.
18. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev 2010; CD00171.
19. Whalen C C, Johnson J L, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 801-808. (Pubitemid 27391629)
20. Quigley M A, Mwinga A, Hosp M, et al. Long term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222. (Pubitemid 32142297)
21. Charalambous S, Grant A D, Innes C, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010; 24 (Suppl 5): S5-S13.
22. Kabali C, von Reyn C F, Brooks D R, et al. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania. Int J Tuberc Lung Dis 2011; 15: 1515-1521.
23. Samandari T, Agizew T B, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
24. Dodd L E, Wilkinson R J. Isoniazid preventive therapy in HIV infection. Lancet 2011; 377: 1548-1550.
25. Golub J E, Saraceni V, Cavalcante S C, et al. The impact of a ntiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-1448. (Pubitemid 46988004)
26. Fenner L, Rieder H L. Isoniazid preventive therapy for all: are we ready? Int J Tuberc Lung Dis 2011; 15: 1281-1282.
27. von Reyn C F, Vuola J. New vaccines for the prevention of tuberculosis. Clin Infect Dis 2002; 35: 465-474.
28. Mansoor N, Scriba T J, de Kock M, et al. HIV-1 infection in infants severely impairs the immune response induced by bacille Calmette-Guerin vaccine. J Infect Dis 2009; 199: 982-990.
29. Hesseling A C, Rabie H, Marais B J, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006; 42: 548-558. (Pubitemid 43202529)
30. Hesseling A C, Cotton M F, von Reyn C F, Graham S M, Gie R P, Hussey G D. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008; 12: 1376-1379.
31. Karonga Trial Prevention Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348: 17-24.
32. Rodrigues L C, Pereira S M, Cunha S S, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster randomized trial. Lancet 2005; 366: 1290-1295. (Pubitemid 41416584)
33. Fine P E M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339-1345.
34. Flahiff E W. The occurrence of tuberculosis in persons who failed to react to tuberculin, and in persons with positive tuberculin reactions. Am J Hyg 1939; 30: 69-74.
35. Lahey T, von Reyn C F. BCG and new vaccines against tuberculosis. In: Schlossberg D, ed. Tuberculosis and non-tuberculous mycobacteria, 6th ed. Washington DC, USA: American Society for Microbiology, 2011.
36. von Reyn C F, Arbeit R D, Yeaman G, et al. Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series. Clin Infect Dis 1997; 24: 843-848. (Pubitemid 27193865)
37. Marsh B J, von Reyn C F, Arbeit R D, Morin P. Immunization of HIV-infected adults with a three-dose series of inactivated Mycobacterium vaccae. Am J Med Sci 1997; 313: 377-383. (Pubitemid 27249095)
38. Johnson D, Waddell R D, Pelton S I, et al. Randomized trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection. Vaccine 1999; 17: 2583-2587.
39. von Reyn C F, Marsh B J, Waddell R, et al. Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus positive subjects in the United States after a five dose schedule of Mycobacterium vaccae vaccine. Clin Infect Dis 1998; 27: 1517-1520. (Pubitemid 29242431)
40. Waddell R D, Chintu C, Lein D, et al. Safety and immunogenicity of a 5 dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis 2000; 30 (Suppl 3): S309-S315.
41. Vuola J, Ristola M, Cole B, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIVa ssociated tuberculosis: a randomized, controlled trial. AIDS 2003; 17: 2351-2355. (Pubitemid 38147021)
42. Munseri P J, Talbot E A, Mtei L, von Reyn C F. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 2008; 12: 1037-1041.
43. Lahey T, Arbeit R D, Bakari M, et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a Phase III study in Tanzania. Vaccine 2010; 28: 7652-7658.
44. Mtei L, Matee M, Herfort O, Bakari M, et al. High rates of clinical and subclinical tuberculosis among ambulatory HIV-positive subjects in Tanzania. Clin Infect Dis 2005; 40: 1500-1507.
45. Kaufmann S H, Hussey G, Lambert P H. New vaccines for tuberculosis. Lancet 2010; 375: 2110-2119.
46. Hoft D F. Tuberculosis vaccine development: goals, immunological design and evaluation. Lancet 2008; 372: 164-175. (Pubitemid 351952260)
47. Minassian A M, Rowland R, Beveridge N E, et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 2011; 1: e000223.
48. von Reyn C F. Optimal treatment of co-disease due to HIV and tuberculosis. J Infect Dis 2011; 204: 884-892.
49. World Health Organization. Guidelines for intensified casefinding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO, 2011: 1-49.